Expression of interleukin-22 in murine carcinoma cells did not influence tumour growth in vivo but did improve survival of the inoculated hosts

Scandinavian Journal of Immunology

Volumn 60, Issue 5, 2004, Pages 449-454

  Nagakawa, H ^a,b   Shimozato, O ^a   Yu, L ^a   Takiguchi, Y ^b   Tatsumi, K ^b   Kuriyama, T ^b   Tagawa, M ^a  

^a CHIBA CANCER CENTER   (Japan)

^b CHIBA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CD3 ANTIBODY; CD3 ANTIGEN; CD40 ANTIBODY; CD40 ANTIGEN; CONCANAVALIN A; CYTOKINE; INTERLEUKIN 10; INTERLEUKIN 22; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER SURVIVAL; CARCINOMA CELL; CELL SURVIVAL; COLON CARCINOMA; CONTROLLED STUDY; GENE; GENE EXPRESSION; GENE INDUCTION; IL 10R2 GENE; IL 22 GENE; IL 22R GENE; IMMUNOCOMPETENT CELL; INFLAMMATION; ISOGRAFT; METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPLEEN CELL; T LYMPHOCYTE ACTIVATION; TUMOR GROWTH;

ANIMALS; CARCINOMA; INTERLEUKINS; MICE; RECEPTORS, INTERLEUKIN; SPLEEN; T-LYMPHOCYTES; TUMOR CELLS, CULTURED;

EID: 8444223078     PISSN: 03009475     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.0300-9475.2004.01504.x     Document Type: Article

References (19)

1. Abbas AK, Murphy KM, Sher A. Functional diversity of helper T lymphocytes. Nature 1996;383:787-93.
2. Tagawa M. Cytokine therapy for cancer. Curr Pharm Des 2000;6:681-99.
3. Roth JA, Cristiano RJ. Gene therapy for cancer: What have we done and where are we going? J Natl Cancer Inst 1997;89:21-39.
4. Zheng LM, Ojcius DM, Garaud F et al. Interleukin-10 inhibits tumor metastasis through an NK cell-dependent mechanism. J Exp Med 1996;184:579-84.
5. Kundu N, Beaty TL, Jackson MJ, Fulton AM. Antimetastatic and antitumor activities of interleukin 10 in a murine model of breast cancer. J Natl Cancer Inst 1996;88:536-41.
6. Stearns ME, Wang M. Antimestatic and antitumor activities of interleukin 10 in transfected human prostate PC-3 ML clones: Orthotopic growth in severe combined immunodeficient mice. Clin Cancer Res 1998;4:2257-63.
7. Sauane M, Gopalkrishnan RV, Sarkar D et al. MDA-7/IL-24: novel cancer growth suppressing and apoptosis inducing cytokine. Cytokine Growth Factor Rev 2003;14:35-51.
8. Caudell EG, Mumm JB, Poindexter N et al. The protein product of the tumor suppressor gene, melanoma differentiation-associated gene 7, exhibits immunostimulatory activity and is designated IL-24. J Immunol 2002;168:6041-6.
9. Dumoutier I, Louahed J, Renauld JC. Cloning and characterization of IL-10-related T cell-derived inducible factor (IL-TIF), a novel cytokine structurally related to IL-10 and inducible by IL-9. J Immunol 2000;164:1814-9.
10. Dumoutier L, Van Roost E, Colau D, Renauld JC. Human interleukin-10- related T cell-derived inducible factor: molecular cloning and functional characterization as an hepatocyte-stimulating factor. Proc Natl Acad Sci USA 2000;97:10l44-9.
11. Kotenko SV. The family of IL-10-related cytokines and their receptors: related, but to what extent? Cytokine Growth Factor Rev 2002;13:223-40.
12. Wolk K, Kunz S, Asadullah K, Sabat R. Immune cells as sources and targets of the IL-10 family members? J Immunol 2002;168: 5397-402.
13. Xie M-H, Aggarwal S, Ho W-H et al. Interleukin (IL)-22, a novel human cytokine that signals through the Interferon receptor-related proteins CRF2-4 and IL-22R. J Biol Chem 2000;275: 31335-9.
14. Tachiiri A, Imamura R, Wang Y, Fukui M, Umemura M, Suda T. Genomic structure and inducible expression of the IL-22 receptor α chain in mice. Genes Immun 2003;4:153-9.
15. Aggarwal S, Xie MH, Maruoka M, Foster J, Gurney AL. Acinar cells of the pancreas are a target of interleukin-22. J Interferon Cytokine Res 2001;21:1047-53.
16. Yoshida H, Tanabe M, Miyauchi M et al. Induced immunity by expression of interleukin-2 or GM-CSF gene in murine neuroblastoma cells can generate antitumor response to established tumors. Cancer Gene Ther 1999;6:395-401.
17. Yoshino S, Tabata T, Hazama S et al. Immunoregulatory effects of the antitumor polysaccharide lentinan on Th1/Th2 balance in patients with digestive cancers. Anticancer Res 2000;20: 4707-11.
18. Mold C, Rodriguez W, Rodic-Polic B, Du Clos TW. C-reactive protein mediates protection from lipopolysaccharide through interactions with Fc gamma R. J Immunol 2002;169: 7019-25.
19. Lécart S, Morel F, Noraz N et al. IL-22, in contrast to IL-10, does not induce Ig production, due to absence of a functional IL-22 receptor on activated human B cells. Int Immunol 2002;14: 1351-6.